Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. More Details
Mediocre balance sheet with limited growth.
Share Price & News
How has Poxel's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: POXEL is less volatile than 75% of French stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: POXEL's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: POXEL underperformed the French Biotechs industry which returned 29% over the past year.
Return vs Market: POXEL underperformed the French Market which returned 42.8% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Poxel's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall StIs Poxel (EPA:POXEL) Weighed On By Its Debt Load?
1 month ago | Simply Wall StPoxel (EPA:POXEL) Share Prices Have Dropped 49% In The Last Five Years
4 months ago | Simply Wall StHow Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?
Is Poxel undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate POXEL's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate POXEL's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: POXEL is unprofitable, so we can't compare its PE Ratio to the XE Biotechs industry average.
PE vs Market: POXEL is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate POXEL's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: POXEL is overvalued based on its PB Ratio (6.9x) compared to the FR Biotechs industry average (4.5x).
How is Poxel forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: POXEL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: POXEL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: POXEL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: POXEL's revenue (22.9% per year) is forecast to grow faster than the French market (6.8% per year).
High Growth Revenue: POXEL's revenue (22.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if POXEL's Return on Equity is forecast to be high in 3 years time
How has Poxel performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: POXEL is currently unprofitable.
Growing Profit Margin: POXEL is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: POXEL is unprofitable, and losses have increased over the past 5 years at a rate of 8.2% per year.
Accelerating Growth: Unable to compare POXEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: POXEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (18.9%).
Return on Equity
High ROE: POXEL has a negative Return on Equity (-118.52%), as it is currently unprofitable.
How is Poxel's financial position?
Financial Position Analysis
Short Term Liabilities: POXEL's short term assets (€46.0M) exceed its short term liabilities (€16.5M).
Long Term Liabilities: POXEL's short term assets (€46.0M) exceed its long term liabilities (€21.7M).
Debt to Equity History and Analysis
Debt Level: POXEL's debt to equity ratio (84.2%) is considered high.
Reducing Debt: POXEL's debt to equity ratio has increased from 10.4% to 84.2% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: POXEL has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if POXEL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Poxel current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate POXEL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate POXEL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if POXEL's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if POXEL's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of POXEL's dividend in 3 years as they are not forecast to pay a notable one for the French market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Thomas Kuhn, PharmD, MBA co-founded Poxel SA in 2009 and serves as its Chief Executive Officer and its Director since June 23, 2010. Mr. Kuhn joined Merck Serono in 2000, where he held various position...
CEO Compensation Analysis
Compensation vs Market: Thomas's total compensation ($USD534.14K) is about average for companies of similar size in the French market ($USD467.32K).
Compensation vs Earnings: Thomas's compensation has increased whilst the company is unprofitable.
Experienced Management: POXEL's management team is seasoned and experienced (6 years average tenure).
Experienced Board: POXEL's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.
Poxel S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Poxel S.A.
- Ticker: POXEL
- Exchange: ENXTPA
- Founded: 2009
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €185.131m
- Shares outstanding: 28.57m
- Website: https://www.poxelpharma.com
Number of Employees
- Poxel S.A.
- Immeuble Le Sunway
- 259-261 Avenue Jean Jaurès
Poxel S.A., a biopharmaceutical company, develops drugs for metabolic diseases with primary focus on type II diabetes. Its lead product is Imeglimin, an oral anti-diabetic candidate, which is in Phase III ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/05/07 20:47|
|End of Day Share Price||2021/05/07 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.